Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Shots:Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infectionsHe also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countriesThe interview summarizes how Shionogi is advancing by developing medicines to treat serious…

BySenior EditorNovember 7, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2019

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA approved 59 novel products including 42 New Chemical Entities and 17 Biologics while breaking its last year's record of approvals. However, there is a significant…

BySenior EditorDecember 13, 2019

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Insights+: The US FDA New Drug Approvals in November 2019

Contact US

OUR INFORMATION

FOLLW US

Simon Portsmouth, VP, Head of Clinical Development, Shionogi Shares Insights from the New Data on an Antibiotic to Treat Bacterial Infections

Insights+: The US FDA New Drug Approvals in November 2019

FOLLW US

Sign Up to Our Newsletter